Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 344

1.

Evaluation of Light Fluence Distribution Using an IR Navigation System for HPPH-mediated Pleural Photodynamic Therapy (pPDT).

Zhu TC, Ong Y, Kim MM, Liang X, Finlay JC, Dimofte A, Simone Nd CB, Friedberg JS, Busch TM, Glatstein E, Cengel KA.

Photochem Photobiol. 2019 Sep 25. doi: 10.1111/php.13166. [Epub ahead of print]

PMID:
31556122
2.

Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death.

Song CW, Glatstein E, Marks LB, Emami B, Grimm J, Sperduto PW, Kim MS, Hui S, Dusenbery KE, Cho LC.

Int J Radiat Oncol Biol Phys. 2019 Mar 2. pii: S0360-3016(19)30291-3. doi: 10.1016/j.ijrobp.2019.02.047. [Epub ahead of print]

PMID:
30836165
3.

PDT dose dosimetry for Photofrin-mediated pleural photodynamic therapy (pPDT).

Ong YH, Kim MM, Finlay JC, Dimofte A, Singhal S, Glatstein E, Cengel KA, Zhu TC.

Phys Med Biol. 2017 Dec 29;63(1):015031. doi: 10.1088/1361-6560/aa9874.

4.

Rapid Decrease in Rates of Hospitalization Resulting From Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Children Aged <60 Months After 13-Valent Pneumococcal Conjugate Vaccine Introduction in Argentina.

López EL, Glatstein E, Ezcurra GC, Iacono M, Teplitz E, Garnero AV, Lazzarini DL, Vázquez M, Contrini MM.

J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):30-35. doi: 10.1093/jpids/piw089.

PMID:
28339727
5.

State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions.

Das IJ, Andersen A, Chen ZJ, Dimofte A, Glatstein E, Hoisak J, Huang L, Langer MP, Lee C, Pacella M, Popple RA, Rice R, Smilowitz J, Sponseller P, Zhu T.

Pract Radiat Oncol. 2017 Mar - Apr;7(2):e145-e155. doi: 10.1016/j.prro.2016.11.003. Epub 2016 Nov 13.

PMID:
28274405
6.

A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy.

Qiu H, Kim MM, Penjweini R, Finlay JC, Busch TM, Wang T, Guo W, Cengel KA, Simone CB 2nd, Glatstein E, Zhu TC.

Photochem Photobiol. 2017 Jul;93(4):1115-1122. doi: 10.1111/php.12719. Epub 2017 Feb 22.

7.

Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.

Friedberg JS, Simone CB 2nd, Culligan MJ, Barsky AR, Doucette A, McNulty S, Hahn SM, Alley E, Sterman DH, Glatstein E, Cengel KA.

Ann Thorac Surg. 2017 Mar;103(3):912-919. doi: 10.1016/j.athoracsur.2016.08.071. Epub 2016 Nov 5.

8.

PDT: What's Past Is Prologue.

Cengel KA, Simone CB 2nd, Glatstein E.

Cancer Res. 2016 May 1;76(9):2497-9. doi: 10.1158/0008-5472.CAN-16-0927.

9.

Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection.

Baumann BC, Nagda SN, Kolker JD, Levin WP, Weber KL, Berman AT, Staddon A, Hartner L, Hahn SM, Glatstein E, Simone CB 2nd.

J Surg Oncol. 2016 Jul;114(1):65-9. doi: 10.1002/jso.24268. Epub 2016 Apr 25.

PMID:
27111504
10.

In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy.

Finlay JC, Zhu TC, Dimofte A, Stripp D, Malkowicz SB, Whittington R, Miles J, Glatstein E, Hahn SM.

Proc SPIE Int Soc Opt Eng. 2014 Jun 14;5315:132-142.

11.

A hypothesis: indirect cell death in the radiosurgery era.

Sperduto PW, Song CW, Kirkpatrick JP, Glatstein E.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):11-3. doi: 10.1016/j.ijrobp.2014.08.355. No abstract available.

PMID:
25835617
12.

The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.

Nagle SJ, Chong EA, Chekol S, Shah NN, Nasta SD, Glatstein E, Plastaras JP, Torigian DA, Schuster SJ, Svoboda J.

Cancer Med. 2015 Jan;4(1):7-15. doi: 10.1002/cam4.322. Epub 2014 Sep 10.

13.

Patients at high risk for recurrence need radiotherapy.

Glatstein E, Plastaras JP.

Clin Adv Hematol Oncol. 2014 Apr;12(4):247, 250-1. No abstract available.

PMID:
25134172
14.

The music of V20: a symphony or cacophony?

Das IJ, Glatstein E.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):973-4. doi: 10.1016/j.ijrobp.2013.12.026. No abstract available.

PMID:
24606859
15.

Radium-223 in prostate cancer.

Vapiwala N, Glatstein E.

N Engl J Med. 2013 Oct 24;369(17):1660. doi: 10.1056/NEJMc1310231. No abstract available.

PMID:
24159608
16.

Fighting prostate cancer with radium-223--not your Madame's isotope.

Vapiwala N, Glatstein E.

N Engl J Med. 2013 Jul 18;369(3):276-8. doi: 10.1056/NEJMe1304041. No abstract available.

PMID:
23863055
17.

Outcomes after involved-field radiation therapy (IFRT) with or without rituximab in patients with early-stage low-grade non-Hodgkin lymphoma (NHL) staged with CT and PET.

Lukens JN, Nasta SD, Fram B, Glatstein E, Plastaras JP.

Am J Clin Oncol. 2014 Feb;37(1):35-40. doi: 10.1097/COC.0b013e31826106c9.

PMID:
22992623
18.

The case for combined-modality therapy for limited-stage Hodgkin's disease.

Hill-Kayser CE, Plastaras JP, Tochner Z, Glatstein E.

Oncologist. 2012;17(8):1006-10. doi: 10.1634/theoncologist.2012-0148. Epub 2012 Jul 17. No abstract available.

19.

Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.

Friedberg JS, Culligan MJ, Mick R, Stevenson J, Hahn SM, Sterman D, Punekar S, Glatstein E, Cengel K.

Ann Thorac Surg. 2012 May;93(5):1658-65; discussion 1665-7. doi: 10.1016/j.athoracsur.2012.02.009.

20.

A real-time treatment guidance system for Pleural PDT.

Zhu TC, Liang X, Sandell J, Finlay JC, Dimofte A, Rodriguez C, Cengel K, Friedberg J, Hahn SM, Glatstein E.

Proc SPIE Int Soc Opt Eng. 2012 Feb 13;8210. pii: 82100A.

21.

Photodynamic therapy for the treatment of non-small cell lung cancer.

Simone CB 2nd, Friedberg JS, Glatstein E, Stevenson JP, Sterman DH, Hahn SM, Cengel KA.

J Thorac Dis. 2012 Feb;4(1):63-75. doi: 10.3978/j.issn.2072-1439.2011.11.05.

22.

The Use of PET in Radiation Therapy for Lymphoma.

Plastaras JP, Geiger G, Perini R, Glatstein E.

PET Clin. 2012 Jan;7(1):67-72. doi: 10.1016/j.cpet.2011.12.005.

PMID:
27157019
23.

Twenty-five year results of the national cancer institute randomized breast conservation trial.

Simone NL, Dan T, Shih J, Smith SL, Sciuto L, Lita E, Lippman ME, Glatstein E, Swain SM, Danforth DN, Camphausen K.

Breast Cancer Res Treat. 2012 Feb;132(1):197-203. doi: 10.1007/s10549-011-1867-6. Epub 2011 Nov 24.

PMID:
22113254
24.

Early-stage Hodgkin disease in a 24-year-old woman.

Peters C, Glatstein E, Vose J, Thomas LC, Morris GJ.

Semin Oncol. 2011 Dec;38(6):705-13. doi: 10.1053/j.seminoncol.2011.06.003. No abstract available.

PMID:
22082755
25.

The omega on alpha and beta.

Glatstein E.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):319-20. doi: 10.1016/j.ijrobp.2011.01.011. No abstract available.

PMID:
21871342
26.

An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values.

López EL, Contrini MM, Glatstein E, Ayala SG, Santoro R, Ezcurra G, Teplitz E, Matsumoto Y, Sato H, Sakai K, Katsuura Y, Hoshide S, Morita T, Harning R, Brookman S.

Pediatr Infect Dis J. 2012 Jan;31(1):20-4. doi: 10.1097/INF.0b013e31822ea6cf.

PMID:
21829137
27.

Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma.

Friedberg JS, Mick R, Culligan M, Stevenson J, Fernandes A, Smith D, Glatstein E, Hahn SM, Cengel K.

Ann Thorac Surg. 2011 Jun;91(6):1738-45. doi: 10.1016/j.athoracsur.2011.02.062.

PMID:
21619970
28.

Short-term and long-term health risks of nuclear-power-plant accidents.

Christodouleas JP, Forrest RD, Ainsley CG, Tochner Z, Hahn SM, Glatstein E.

N Engl J Med. 2011 Jun 16;364(24):2334-41. doi: 10.1056/NEJMra1103676. Epub 2011 Apr 20. Review. No abstract available.

29.

An IR navigation system for real-time treatment guidance of Pleural PDT.

Zhu TC, Liang X, Chang C, Sandell J, Finlay JC, Dimofte A, Rodrigeus C, Cengel K, Friedberg J, Glatstein E, Hahn SM.

Proc SPIE Int Soc Opt Eng. 2011 Feb 28;7886. pii: 78860L.

30.

TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions.

Hill-Kayser CE, Plastaras JP, Tochner Z, Glatstein E.

Bone Marrow Transplant. 2011 Apr;46(4):475-84. doi: 10.1038/bmt.2010.280. Epub 2010 Nov 29. Review.

PMID:
21113184
31.

Reminiscences.

Glatstein E.

Oncologist. 2010;15(4):388-9. doi: 10.1634/theoncologist.2009-S103. No abstract available.

32.

The road not taken and choices in radiation oncology.

Coleman CN, Glatstein E.

Oncologist. 2010;15(4):332-7. doi: 10.1634/theoncologist.2009-S102.

33.

Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.

Fernandes AT, Shen J, Finlay J, Mitra N, Evans T, Stevenson J, Langer C, Lin L, Hahn S, Glatstein E, Rengan R.

Radiother Oncol. 2010 May;95(2):178-84. doi: 10.1016/j.radonc.2010.02.007. Epub 2010 Mar 29.

PMID:
20356642
34.

Distinguishing "controversy" from conflict of interest: the wrong image for radiation oncology.

Glatstein E.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1283-4. doi: 10.1016/j.ijrobp.2009.09.076. No abstract available.

PMID:
20338469
35.

Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli.

López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S.

Antimicrob Agents Chemother. 2010 Jan;54(1):239-43. doi: 10.1128/AAC.00343-09. Epub 2009 Oct 12.

36.

[Vancomycin-resistant enterococci: prevalence and factors associated with intestinal colonization in oncology patients from Hospital de Niños de Córdoba].

Reale AL, Depetri ML, Culasso C, Paviolo M, Cheguirián ML, Enrico MC, Ledesma EM, Vidal C, Glatstein E, Bertoni L.

Rev Argent Microbiol. 2009 Apr-Jun;41(2):92-6. Spanish.

PMID:
19623898
37.

The most important question.

Corn BW, Glatstein E.

Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):985-6. doi: 10.1016/j.ijrobp.2009.03.044. No abstract available.

PMID:
19545783
38.

Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason.

Kelsey CR, Marks LB, Glatstein E.

Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1291-2. doi: 10.1016/j.ijrobp.2008.12.017. No abstract available.

PMID:
19306745
39.

Multidisciplinary team meetings: what does the future hold for the flies raised in Wittgenstein's bottle?

Sharma RA, Shah K, Glatstein E.

Lancet Oncol. 2009 Feb;10(2):98-9. doi: 10.1016/S1470-2045(09)70006-3. No abstract available.

PMID:
19185826
40.

Radiotherapy for early-stage Hodgkin's lymphoma: a 21st century perspective and review of multiple randomized clinical trials.

Bar Ad V, Paltiel O, Glatstein E.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1472-9. doi: 10.1016/j.ijrobp.2008.08.026. Review.

PMID:
19028275
41.

Black, white, or shades of gray?

Glatstein E.

Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1307. doi: 10.1016/j.ijrobp.2008.09.001. No abstract available.

PMID:
19028272
42.

Some cases of severe normal tissue toxicity can be anticipated with ablated fractionated radiation with appropriate long-term follow-up.

Dolinsky C, Glatstein E.

Semin Radiat Oncol. 2008 Oct;18(4):229-33. doi: 10.1016/j.semradonc.2008.04.003.

PMID:
18725108
43.

Hypofractionation, long-term effects, and the alpha/beta ratio.

Glatstein E.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):11-2. doi: 10.1016/j.ijrobp.2008.07.006. No abstract available.

PMID:
18722259
44.

Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma.

Plastaras JP, Glatstein E, Schuster SJ.

Oncologist. 2008 Jun;13(6):655-6. doi: 10.1634/theoncologist.2008-0113. No abstract available.

45.

Should randomized clinical trials be required for proton radiotherapy? An alternative view.

Glatstein E, Glick J, Kaiser L, Hahn SM.

J Clin Oncol. 2008 May 20;26(15):2438-9. doi: 10.1200/JCO.2008.17.1843. Epub 2008 Apr 28. No abstract available.

PMID:
18443345
46.

Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems.

Das IJ, Cheng CW, Chopra KL, Mitra RK, Srivastava SP, Glatstein E.

J Natl Cancer Inst. 2008 Mar 5;100(5):300-7. doi: 10.1093/jnci/djn020. Epub 2008 Feb 26.

PMID:
18314476
47.

Primary cardiac lymphoma: utility of multimodality imaging in diagnosis and management.

Mato AR, Morgans AK, Roullet MR, Bagg A, Glatstein E, Litt HI, Downs LH, Chong EA, Olson ER, Andreadis C, Schuster SJ.

Cancer Biol Ther. 2007 Dec;6(12):1867-70. Epub 2007 Oct 13.

PMID:
18075298
48.

Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.

Wang HW, Rickter E, Yuan M, Wileyto EP, Glatstein E, Yodh A, Busch TM.

Photochem Photobiol. 2007 Sep-Oct;83(5):1040-8.

PMID:
17880498
49.

Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.

Am J Hematol. 2007 Dec;82(12):1071-5.

50.

Intraperitoneal photodynamic therapy.

Cengel KA, Glatstein E, Hahn SM.

Cancer Treat Res. 2007;134:493-514. Review.

PMID:
17633077

Supplemental Content

Loading ...
Support Center